{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:29:32Z","timestamp":1788791372136,"version":"build-2803163510"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Pediatric inflammatory bowel disease (PIBD) has a rising global prevalence, with patients often demonstrating more aggressive and extensive disease activity compared to adult-onset disease. With improved access to therapeutic agents outside of the anti-TNF-\u03b1 class, we seek to provide an updated framework for the management of PIBD patients through use of advanced biologic and small molecule therapies and to give guidance on the use of dual targeted therapy (DTT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Although anti-TNF agents remain first-line options for moderate-to-severe Crohn's disease and ulcerative colitis, emerging pediatric clinical trial and real-world data support the use of vedolizumab and ustekinumab as second-line therapies. While PIBD-specific data are limited, novel anti-IL-23p19 agents and oral Janus kinase inhibitors (JAKi) have shown promising results for refractory disease. Emerging evidence supports the use of DTT for PIBD patients who do not achieve remission endpoints with use of a single agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Early aggressive intervention with advanced therapies leads to improved clinical outcomes in PIBD patients with moderate-to-severe disease activity. Proactive therapeutic drug monitoring (TDM) and strategic use of DTT allow for improved durability of therapy and better clinical remission rates. Additional pediatric studies are needed to properly position novel anti-IL-23p19 and JAKi agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001592","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:00:13Z","timestamp":1782496813000},"page":"493-501","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advanced therapies in management of pediatric inflammatory bowel disease"],"prefix":"10.1097","volume":"38","author":[{"given":"Justin","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Gurram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"R1-20260907","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"R2-20260907","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.gastro.2020.07.066","article-title":"Predicting outcomes in pediatric ulcerative colitis for management optimization: systematic review and consensus statements from the Pediatric Inflammatory Bowel Disease-Ahead Program","volume":"160","author":"Orlanski-Meyer","year":"2021","journal-title":"Gastroenterology"},{"key":"R3-20260907","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/MPG.0000000000001898","article-title":"Molecular comparison of adult and pediatric ulcerative colitis indicates broad similarity of molecular pathways in disease tissue","volume":"67","author":"Li","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R4-20260907","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet"},{"key":"R5-20260907","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s00431-021-04063-6","article-title":"Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study","volume":"180","author":"Garcia-Romero","year":"2021","journal-title":"Eur J Pediatr"},{"key":"R6-20260907","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R7-20260907","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R8-20260907","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut"},{"key":"R9-20260907","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology"},{"key":"R10-20260907","doi-asserted-by":"crossref","DOI":"10.1002\/jpn3.70396","article-title":"Evaluating the impact of therapeutic drug monitoring strategies on clinical outcomes in paediatric inflammatory bowel disease","author":"Hubert","year":"2026","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R11-20260907","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2468-1253(24)00319-4","article-title":"Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study","volume":"10","author":"Atia","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R12-20260907","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/ecco-jcc\/jjac036","article-title":"Pharmacokinetics, safety and efficacy of intravenous vedolizumab in paediatric patients with ulcerative colitis or Crohn's disease: results from the Phase 2 HUBBLE Study","volume":"16","author":"Hyams","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R13-20260907","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1007\/s00431-024-05588-2","article-title":"STEP-CD study: ustekinumab use in paediatric Crohn's disease\u2014a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN","volume":"183","author":"Pujol-Muncunill","year":"2024","journal-title":"Eur J Pediatr"},{"key":"R14-20260907","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/MPG.0000000000002091","article-title":"Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful","volume":"67","author":"Gervais","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R15-20260907","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjag011","article-title":"Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40\u200akg","volume":"20","author":"De Greef","year":"2026","journal-title":"J Crohns Colitis"},{"key":"R16-20260907","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1: Ambulatory Care-An Evidence-based Guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R17-20260907","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/apt.70016","article-title":"Upadacitinib for induction of remission in paediatric Crohn's disease: an international multicentre retrospective study","volume":"61","author":"Cohen","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20260907","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/ibd\/izae112","article-title":"Tofacitinib in pediatric ulcerative colitis: a retrospective multicenter experience","volume":"31","author":"Ledder","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"R19-20260907","doi-asserted-by":"crossref","first-page":"jjae182","DOI":"10.1093\/ecco-jcc\/jjae182","article-title":"Upadacitinib for induction of remission in pediatric ulcerative colitis: an international multicenter study","volume":"19","author":"Yerushalmy-Feler","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R20-20260907","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2026.02.012","article-title":"Upadacitinib maintenance therapy in pediatric ulcerative colitis: 52-week multicenter study from the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition","author":"Yerushalmy-Feler","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R21-20260907","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","article-title":"Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease","volume":"27","author":"Dolinger","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R23-20260907","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"R24-20260907","doi-asserted-by":"crossref","first-page":"354","DOI":"10.14309\/ajg.0000000000002053","article-title":"Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease","volume":"118","author":"Egberg","year":"2022","journal-title":"American Journal of Gastroenterology"},{"key":"R25-20260907","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risks of Serious Infection or Lymphoma With Anti\u2013Tumor Necrosis\u00a0Factor Therapy for Pediatric Inflammatory Bowel Disease: A\u00a0Systematic Review","volume":"12","author":"Dulai","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"R26-20260907","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","article-title":"Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease","volume":"34","author":"Murch","year":"1993","journal-title":"Gut"},{"key":"R27-20260907","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"R28-20260907","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"R29-20260907","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ibd.23023","article-title":"Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis","volume":"19","author":"Perrier","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R30-20260907","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"R31-20260907","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ibd.20845","article-title":"Long-term outcome of maintenance infliximab therapy in children with Crohn's disease","volume":"15","author":"Hyams","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R32-20260907","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.19609.1","article-title":"Recent advances in understanding and managing pediatric inflammatory bowel disease","volume":"8","author":"Gurram","year":"2019","journal-title":"F1000Res"},{"key":"R33-20260907","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with antitumor necrosis factor-\u03b1 vs an immunomodulator in children with Crohn's disease","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"key":"R34-20260907","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"R35-20260907","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MIB.0000000000001021","article-title":"Long-term efficacy and safety of adalimumab in pediatric patients with Crohn's disease","volume":"23","author":"Faubion","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R36-20260907","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study","volume":"6","author":"Croft","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R37-20260907","doi-asserted-by":"crossref","first-page":"e00490","DOI":"10.14309\/ctg.0000000000000490","article-title":"Adalimumab vs infliximab in pediatric patients with Crohn's disease: a propensity score analysis and predictors of treatment escalation","volume":"13","author":"Bronsky","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"R38-20260907","first-page":"13","article-title":"Efficacy of adalimumab as second-line therapy in a pediatric cohort of crohn's disease patients who failed infliximab therapy: the Italian society of pediatric gastroenterology, hepatology, and nutrition experience","volume":"13","author":"Alvisi","year":"2019","journal-title":"Biologics"},{"key":"R39-20260907","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/MPG.0000000000001883","article-title":"Efficacy and safety of adalimumab in pediatric ulcerative colitis: a real-life experience from the SIGENP-IBD Registry","volume":"66","author":"Aloi","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R40-20260907","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1097\/MIB.0000000000001262","article-title":"Subcutaneous golimumab in pediatric ulcerative colitis","volume":"23","author":"Hyams","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R41-20260907","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5223\/pghn.2022.25.6.461","article-title":"Long-term efficacy and safety of golimumab for ulcerative colitis in a pediatric inflammatory bowel disease center in Japan","volume":"25","author":"Tokita","year":"2022","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"R42-20260907","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/ibd\/izaf322","article-title":"Efficacy, safety, and pharmacokinetics of golimumab in children with moderately-to-severely active ulcerative colitis: results from the PURSUIT 2 Study","volume":"32","author":"Turner","year":"2026","journal-title":"Inflamm Bowel Dis"},{"key":"R44-20260907","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"R45-20260907","doi-asserted-by":"crossref","first-page":"e2022058037","DOI":"10.1542\/peds.2022-058037","article-title":"Pediatric inflammatory bowel disease","volume":"151","author":"Bouhuys","year":"2023","journal-title":"Pediatrics"},{"key":"R47-20260907","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/jgh.16246","article-title":"Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan","volume":"38","author":"Yokoyama","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"R48-20260907","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN Guideline Update","volume":"15","author":"Van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R49-20260907","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40272-024-00631-z","article-title":"Effectiveness and safety of ustekinumab in pediatric ulcerative colitis: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN","volume":"26","author":"Cohen","year":"2024","journal-title":"Pediatric Drugs"},{"key":"R50-20260907","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/apt.16388","article-title":"One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study","volume":"53","author":"Dhaliwal","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R51-20260907","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/jpn3.70372","article-title":"Effectiveness and safety of ustekinumab in pediatric Crohn's disease: results of the REALITI study","volume":"82","author":"Steiner","year":"2026","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R53-20260907","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S2468-1253(25)00196-7","article-title":"Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, nonrandomised phase 2 trial","volume":"11","author":"Kaplan","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R54-20260907","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/ibd\/izaf291","article-title":"Real-world effectiveness of and optimization strategies for mirikizumab in pediatric ulcerative colitis: a prospective, observational study","volume":"32","author":"Jimbo","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"R55-20260907","first-page":"656","article-title":"Infliximab biosimilar utilization in a large pediatric learning health system","volume":"12","author":"Maltz","year":"2025","journal-title":"Children (Basel)"},{"key":"R56-20260907","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations","volume":"10","author":"Sieczkowska","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R57-20260907","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MPG.0000000000002011","article-title":"Use of infliximab biosimilar versus originator in a pediatric United Kingdom inflammatory bowel disease induction cohort","volume":"67","author":"Chanchlani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R58-20260907","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12519-024-00873-4","article-title":"Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System","volume":"21","author":"Jourdain","year":"2025","journal-title":"World J Pediatr"},{"key":"R59-20260907","doi-asserted-by":"crossref","DOI":"10.1002\/jpn3.70381","article-title":"Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States","author":"Young","year":"2026","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R60-20260907","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"R61-20260907","first-page":"265","article-title":"Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease","volume":"18","author":"Choden","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R63-20260907","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MPG.0000000000001672","article-title":"Long-term outcomes of infliximab use for pediatric Crohn disease: a Canadian multicenter clinical practice experience","volume":"66","author":"DeBruyn","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R64-20260907","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2023.03.224","article-title":"Comparative effectiveness of anti-TNF in combination with low-dose methotrexate vs anti-TNF monotherapy in pediatric Crohn's disease: a pragmatic randomized trial","volume":"165","author":"Kappelman","year":"2023","journal-title":"Gastroenterology"},{"key":"R65-20260907","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","article-title":"Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease","volume":"34","author":"Murch","year":"1993","journal-title":"Gut"},{"key":"R66-20260907","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"R67-20260907","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1053\/j.gastro.2025.09.038","article-title":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease","volume":"169","author":"Scott","year":"2025","journal-title":"Gastroenterology"},{"key":"R68-20260907","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ibd\/izad064","article-title":"Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): a multicenter study from the Pediatric IBD Porto Group of ESPGHAN","volume":"30","author":"Yerushalmy-Feler","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R69-20260907","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/MPG.0000000000001850","article-title":"The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition","volume":"66","author":"Day","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0000000000001592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:00:47Z","timestamp":1788789647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0000000000001592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001592","relation":{},"ISSN":["1531-698X","1040-8703"],"issn-type":[{"value":"1531-698X","type":"electronic"},{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}